Formulary Search

You are here : Home > Formulary Search

I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.

Return to the search options.

A-Z of Drugs : A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

A-Z of Drugs

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Search Results : Crohn's disease (Methotrexate - Inflammatory bowel disease)

Records returned : 40 (on 04 Aug 2026 at 04:41:41). Return to search results for ' Crohn's disease '.

Show Icon and Status Keys Hide Icon and Status Keys

Icon Key

NFD1

Non formulary

NFD2

Not assessed for formulary status. Apply to APC / DTC before use.

Controlled drug. Prescribing and/or storage requirements may apply

Restrictions apply

Safety Alert

Unlicensed - no UK marketing license in place

Off Label

Not licensed for this indication.

NHSE

Treatment commissioned by NHS England

CDF

Cancer Drugs Fund

ICB

Treatment commissioned by the ICB

BlueTeq form to be completed

NICE

Link to the NICE website

Low carbon device

SPC

View the treatment summary for {padindicationname} on https://www.medicines.org.uk

Status Key

Red

Specialist ONLY drugs - treatment initiated and continued by specialist clinicians

Amber

Prescribing initiated and stabilised by specialist but has potential to transfer to primary care under a formal shared care agreement

Green

GPs (or non-medical prescribers in primary care) are able to take full responsibility for initiation and continuation of prescribing.

Green (see narrative)

GPs (or non-medical prescribers in primary care) are able to take full responsibility for initiation and continuation of prescribing. Please refer to the narrative on the Drug Profile page where additional information may be conveyed as to the place in therapy or restrictions for use that have been locally agreed.

Non Formulary

Not recommended for use in any health setting across the Surrey Heartlands Integrated Care System

Blue

Prescribing initiated and stabilised by specialist but has potential to transfer to primary care WITHOUT a formal shared care agreement. Please note that in some circumstances a specialist may recommend that prescribing can be started in primary care.

See narrative

See narrative - may be applied in instances where a traffic light status has not yet been agreed but an entry to the formulary has been made to clarify interim arrangements.

Drug

Indication

Status

Restrictions/Comments

Formulary Status

Links

1. Methotrexate

Drug:

Methotrexate

Indication :

Inflammatory bowel disease

Status :

Amber

Formulations :

Injection
Tablets

Restrictions / Comments:

Important

DO NOT prescribe or supply 10mg tablets. WEEKLY dose frequency. Advise patients to carry the patient alert card / book - https://www.gov.uk/drug-safety-update/methotrexate-once-weekly-for-autoimmune-diseases-new-measures-to-reduce-risk-of-fatal-overdose-due-to-inadvertent-daily-instead-of-weekly-dosing

Photosensitivity risk - https://www.gov.uk/drug-safety-update/methotrexate-advise-patients-to-take-precautions-in-the-sun-to-avoid-photosensitivity-reactions

Click on drug name for specific shared care document.

General principles for shared care found here: https://surrey.res.services/PAD/Profile/NonClinicalProfile/9136

Formulary Status :

Primary Care

ASPH

RSFT

SASH

SABP

Links :

Guidelines

SPC

2. Budesonide

Drug:

Budesonide

Indication :

Inflammatory bowel disease

Status :

Green

Formulations :

Foam enema

Restrictions / Comments:

Important

Steroid safety considerations

Formulary Status :

Primary Care

ASPH

RSFT

SASH

SABP

Links :

Guidelines

SPC

18. Budesonide

Drug:

Budesonide

Indication :

Inflammatory bowel disease

Status :

Red

Formulations :

Gastro-resistant capsules
Modified release capsules

Restrictions / Comments:

Important

Steroid safety considerations

3mg MR and immediate-release gastro-resistant capsules - specialist only

Formulary Status :

Primary Care

ASPH

RSFT

SASH

SABP

Links :

Guidelines

SPC

19. Budesonide

Drug:

Budesonide

Indication :

Inflammatory bowel disease

Status :

Red

Formulations :

Sachets (granules)

Restrictions / Comments:

Important

Steroid safety considerations

RSFT gastroenterology only.

Formulary Status :

Primary Care

ASPH

RSFT

SASH

SABP

Links :

Guidelines

SPC

40. Budesonide

Drug:

Budesonide

Indication :

Inflammatory bowel disease

Status :

See narrative

Formulations :

Suppositories

Restrictions / Comments:

Important

Steroid safety considerations

Not assessed for formulary status. Applications for formulary entry via APC.

Formulary Status :

Primary Care

ASPH

RSFT

SASH

SABP

Links :

Guidelines

NFD2

SPC

3. Prednisolone

Drug:

Prednisolone

Indication :

Inflammatory bowel disease

Status :

Green

Formulations :

Tablets

Restrictions / Comments:

Important

Tablets can be dispersed for immediate administration.

Formulary Status :

Primary Care

ASPH

RSFT

SASH

SABP

Links :

Guidelines

SPC

4. Prednisolone

Drug:

Prednisolone

Indication :

Inflammatory bowel disease

Status :

Green

Formulations :

Soluble tablets

Restrictions / Comments:

Important

Paediatrics only at SASH. Paediatrics and oncology at ASPH

Formulary Status :

Primary Care

ASPH

RSFT

SASH

SABP

Links :

Guidelines

SPC

5. Prednisolone

Drug:

Prednisolone

Indication :

Inflammatory bowel disease

Status :

Green

Formulations :

Oral solution

Restrictions / Comments:

Important

Paediatric doses and NG/NJ tube only

Formulary Status :

Primary Care

ASPH

RSFT

SASH

SABP

Links :

Guidelines

SPC

38. Prednisolone

Drug:

Prednisolone

Indication :

Inflammatory bowel disease

Status :

Non Formulary

Formulations :

Foam enema

Restrictions / Comments:

Important

Budesonide rectal foam is preferred. Steroid safety considerations

Formulary Status :

Primary Care

ASPH

RSFT

SASH

SABP

Links :

Guidelines

NFD1

SPC

39. Prednisolone

Drug:

Prednisolone

Indication :

Inflammatory bowel disease

Status :

Non Formulary

Formulations :

Gastro-resistant tablets

Restrictions / Comments:

Important

Enteric coated tablets - non-formulary

Formulary Status :

Primary Care

ASPH

RSFT

SASH

SABP

Links :

Guidelines

NFD1

SPC

6. Mesalazine

Drug:

Mesalazine

Indication :

Inflammatory bowel disease

Status :

Green (see narrative)

Formulations :

Gastro-resistant tablets

Restrictions / Comments:

Important

Preferred

Ulcerative colitis only. GP may initiate following diagnosis or advice from specialist. Refer to the Ulcerative Colitis pathway.

Prescribe by brand.: Octasa or Salofalk gastro resistant tablets (or Salofalk granules) are 1st line for new patients Asacol tablets are non-formulary

Formulary Status :

Primary Care

ASPH

RSFT

SASH

SABP

Links :

Guidelines

SPC

7. Mesalazine

Drug:

Mesalazine

Indication :

Inflammatory bowel disease

Status :

Green (see narrative)

Formulations :

Suppositories

Restrictions / Comments:

Important

Ulcerative colitis only. GP may initiate following diagnosis or advice from specialist. Refer to the Ulcerative Colitis pathway.

Prescribe by brand: Octasa, Salofalk, Pentasa (soon to be known as "Mesalazine Ferring")

Formulary Status :

Primary Care

ASPH

RSFT

SASH

SABP

Links :

Guidelines

SPC

8. Mesalazine

Drug:

Mesalazine

Indication :

Inflammatory bowel disease

Status :

Green (see narrative)

Formulations :

Modified release tablets

Restrictions / Comments:

Important

Ulcerative colitis only. GP may initiate following diagnosis or advice from specialist. Refer to the Ulcerative Colitis pathway.

Mezevant XL - Reserve for patients with a high pill burden.

Formulary Status :

Primary Care

ASPH

RSFT

SASH

SABP

Links :

Guidelines

SPC

9. Mesalazine

Drug:

Mesalazine

Indication :

Inflammatory bowel disease

Status :

Green (see narrative)

Formulations :

Granules (slow release)
Modified release tablets

Restrictions / Comments:

Important

Preferred

Ulcerative colitis only. GP may initiate following diagnosis or advice from specialist. Refer to the Ulcerative Colitis pathway.

Prescribe by brand: Salofalk granules are a 1st-line option for new patients. Pentasa modified-release tablets and granules for patients who require upper GI release.

Formulary Status :

Primary Care

ASPH

RSFT

SASH

SABP

Links :

Guidelines

SPC

10. Mesalazine

Drug:

Mesalazine

Indication :

Inflammatory bowel disease

Status :

Green (see narrative)

Formulations :

Enema
Foam enema

Restrictions / Comments:

Important

Ulcerative colitis only. GP may initiate following diagnosis or advice from specialist. Refer to the Ulcerative Colitis pathway.

Prescribe by brand: Pentasa / Salofalk enema

Formulary Status :

Primary Care

ASPH

RSFT

SASH

SABP

Links :

Guidelines

SPC

36. Mesalazine

Drug:

Mesalazine

Indication :

Inflammatory bowel disease

Status :

Non Formulary

Formulations :

Gastro-resistant tablets

Restrictions / Comments:

Important

Ulcerative colitis only. GP may initiate following diagnosis or advice from specialist. Refer to the Ulcerative Colitis pathway.

Asacol 400mg gastro resitsant tablets have been discontinued. The 800mg tablets are non-formulary.

Formulary Status :

Primary Care

ASPH

RSFT

SASH

SABP

Links :

Guidelines

SPC

11. Allopurinol

Drug:

Allopurinol

Indication :

Inflammatory bowel disease

Status :

Amber

Formulations :

Tablets

Restrictions / Comments:

Important

Off-label use in combination with azathioprine and mercaptopurine

Formulary Status :

Primary Care

ASPH

RSFT

SASH

SABP

Links :

Guidelines

Off Label

SPC

12. Azathioprine

Drug:

Azathioprine

Indication :

Inflammatory bowel disease

Status :

Amber

Formulations :

Oral suspension
Tablets

Restrictions / Comments:

Important

Click on drug name for specific shared care document.

General principles for shared care found here: https://surrey.res.services/PAD/Profile/NonClinicalProfile/9136

https://www.gov.uk/drug-safety-update/thiopurines-and-intrahepatic-cholestasis-of-pregnancy

Formulary Status :

Primary Care

ASPH

RSFT

SASH

SABP

Links :

Guidelines

SPC

13. Mercaptopurine

Drug:

Mercaptopurine

Indication :

Inflammatory bowel disease

Status :

Amber

Formulations :

Oral suspension
Tablets

Restrictions / Comments:

Important

Tablets and oral suspension are NOT bioequivalent. Do not confuse with mercaptamine (similar name) - https://www.gov.uk/drug-safety-update/mercaptamine-and-mercaptopurine-confusion-between-drug-names

https://www.gov.uk/drug-safety-update/thiopurines-and-intrahepatic-cholestasis-of-pregnancy

Click on drug name for specific shared care document.

General principles for shared care found here: https://surrey.res.services/PAD/Profile/NonClinicalProfile/9136

Formulary Status :

Primary Care

ASPH

RSFT

SASH

SABP

Links :

Guidelines

Off Label

SPC

14. Sulfasalazine

Drug:

Sulfasalazine

Indication :

Inflammatory bowel disease

Status :

Amber

Formulations :

Oral suspension
Tablets

Restrictions / Comments:

Important

Click on drug name for specific shared care document.

General principles for shared care found here: https://surrey.res.services/PAD/Profile/NonClinicalProfile/9136

Formulary Status :

Primary Care

ASPH

RSFT

SASH

SABP

Links :

Guidelines

SPC

15. Sulfasalazine

Drug:

Sulfasalazine

Indication :

Inflammatory bowel disease

Status :

Amber

Formulations :

Gastro-resistant tablets

Restrictions / Comments:

Important

Click on drug name for specific shared care document.

General principles for shared care found here: https://surrey.res.services/PAD/Profile/NonClinicalProfile/9136

Enteric coated tablets are significantly more expensive. Reserve for patients unable to tolerate plain tablets.

Formulary Status :

Primary Care

ASPH

RSFT

SASH

SABP

Links :

Guidelines

SPC

16. Sulfasalazine

Drug:

Sulfasalazine

Indication :

Inflammatory bowel disease

Status :

Amber

Formulations :

Suppositories

Restrictions / Comments:

Important

Click on drug name for specific shared care document.

General principles for shared care found here: https://surrey.res.services/PAD/Profile/NonClinicalProfile/9136

Formulary Status :

Primary Care

ASPH

RSFT

SASH

SABP

Links :

Guidelines

SPC

17. Adalimumab

Drug:

Adalimumab

Indication :

Inflammatory bowel disease

Status :

Red

Formulations :

Subcutaneous injection (sc)

Restrictions / Comments:

Important

For UC & CD. Adults only. Prescribe by brand.

Formulary Status :

Primary Care

ASPH

RSFT

SASH

SABP

Links :

Guidelines

ICB

NICE

SPC

20. Ciclosporin

Drug:

Ciclosporin

Indication :

Inflammatory bowel disease

Status :

Red

Formulations :

Capsules
Intravenous infusion

Restrictions / Comments:

Important

Ulcerative colitis only. Prescribe by brand

Formulary Status :

Primary Care

ASPH

RSFT

SASH

SABP

Links :

Guidelines

Off Label

SPC

21. Ciclosporin

Drug:

Ciclosporin

Indication :

Inflammatory bowel disease

Status :

Red

Formulations :

Oral solution

Restrictions / Comments:

Important

Ulcerative colitis only. Prescribe by brand

Ulcerative colitis only

Formulary Status :

Primary Care

ASPH

RSFT

SASH

SABP

Links :

Guidelines

Off Label

SPC

22. Etrasimod

Drug:

Etrasimod

Indication :

Inflammatory bowel disease

Status :

Red

Formulations :

Tablets

Restrictions / Comments:

Important

Ulcerative colitis only

NICE guidance applies to Ulcerative Colitis patients only

Formulary Status :

Primary Care

ASPH

RSFT

SASH

SABP

Links :

Guidelines

ICB

NICE

SPC

23. Filgotinib

Drug:

Filgotinib

Indication :

Inflammatory bowel disease

Status :

Red

Formulations :

Tablets

Restrictions / Comments:

Important

Ulcerative colitis - adults only

Formulary Status :

Primary Care

ASPH

RSFT

SASH

SABP

Links :

Guidelines

ICB

NICE

SPC

24. Golimumab

Drug:

Golimumab

Indication :

Inflammatory bowel disease

Status :

Red

Formulations :

Subcutaneous injection (sc)

Restrictions / Comments:

Important

Ulcerative Colitis in Adults only. Prescribe by brand.

Formulary Status :

Primary Care

ASPH

RSFT

SASH

SABP

Links :

Guidelines

ICB

NICE

SPC

25. Guselkumab

Drug:

Guselkumab

Indication :

Inflammatory bowel disease

Status :

Red

Formulations :

Subcutaneous injection (sc)

Restrictions / Comments:

Important

Preferred

For UC & CD. Prescribe by brand

Formulary Status :

Primary Care

ASPH

RSFT

SASH

SABP

Links :

Guidelines

ICB

NICE

SPC

26. Guselkumab

Drug:

Guselkumab

Indication :

Inflammatory bowel disease

Status :

Red

Formulations :

Intravenous injection (IV)

Restrictions / Comments:

Important

For UC & CD. Prescribe by brand

Formulary Status :

Primary Care

ASPH

RSFT

SASH

SABP

Links :

Guidelines

ICB

NICE

SPC

27. Infliximab

Drug:

Infliximab

Indication :

Inflammatory bowel disease

Status :

Red

Formulations :

Intravenous infusion
Subcutaneous injection (sc)

Restrictions / Comments:

Important

For UC & CD. Prescribe by brand

Formulary Status :

Primary Care

ASPH

RSFT

SASH

SABP

Links :

Guidelines

ICB

NICE

SPC

28. Mirikizumab

Drug:

Mirikizumab

Indication :

Inflammatory bowel disease

Status :

Red

Formulations :

Intravenous infusion
Subcutaneous injection (sc)

Restrictions / Comments:

Important

For UC & CD. Adults only.

Formulary Status :

Primary Care

ASPH

RSFT

SASH

SABP

Links :

Guidelines

ICB

NICE

SPC

29. Ozanimod

Drug:

Ozanimod

Indication :

Inflammatory bowel disease

Status :

Red

Formulations :

Capsules

Restrictions / Comments:

Important

Ulcerative Colitis - adults only.

Formulary Status :

Primary Care

ASPH

RSFT

SASH

SABP

Links :

Guidelines

ICB

NICE

SPC

30. Risankizumab

Drug:

Risankizumab

Indication :

Inflammatory bowel disease

Status :

Red

Formulations :

Intravenous infusion
Subcutaneous injection (sc)

Restrictions / Comments:

Important

For UC & CD. Adults only

Formulary Status :

Primary Care

ASPH

RSFT

SASH

SABP

Links :

Guidelines

ICB

NICE

SPC

31. Tofacitinib

Drug:

Tofacitinib

Indication :

Inflammatory bowel disease

Status :

Red

Formulations :

Tablets

Restrictions / Comments:

Important

Ulcerative colitis - adults only

Tofacitinib (Xeljanz?): new measures to minimise risk of major adverse cardiovascular events and malignancies - GOV.UK

Tofacitinib (Xeljanz?): new measures to minimise risk of venous thromboembolism and of serious and fatal infections - GOV.UK

Tofacitinib (Xeljanz?): restriction of 10 mg twice-daily dose in patients at high risk of pulmonary embolism while safety review is ongoing - GOV.UK

XELJANZ 10 mg film-coated tablets - Risk Management Materials - (emc) | 9410

Formulary Status :

Primary Care

ASPH

RSFT

SASH

SABP

Links :

Guidelines

ICB

NICE

SPC

32. Upadacitinib

Drug:

Upadacitinib

Indication :

Inflammatory bowel disease

Status :

Red

Formulations :

Modified release tablets

Restrictions / Comments:

Important

RINVOQ 15 mg prolonged-release tablets - Risk Management Materials - (emc) | 10972

Formulary Status :

Primary Care

ASPH

RSFT

SASH

SABP

Links :

Guidelines

ICB

NICE

SPC

33. Ustekinumab

Drug:

Ustekinumab

Indication :

Inflammatory bowel disease

Status :

Red

Formulations :

Intravenous infusion
Subcutaneous injection (sc)

Restrictions / Comments:

Important

Adults only.

Formulary Status :

Primary Care

ASPH

RSFT

SASH

SABP

Links :

Guidelines

ICB

NICE

SPC

34. Vedolizumab

Drug:

Vedolizumab

Indication :

Inflammatory bowel disease

Status :

Red

Formulations :

Infusion
Subcutaneous injection (sc)

Restrictions / Comments:

Important

Not 1st line. Only in patients where steroids and/or TNF inhibitor not effective / appropriate

Formulary Status :

Primary Care

ASPH

RSFT

SASH

SABP

Links :

Guidelines

ICB

NICE

SPC

35. Balsalazide sodium

Drug:

Balsalazide sodium

Indication :

Inflammatory bowel disease

Status :

Non Formulary

Formulations :

Not Specified

Restrictions / Comments:

Formulary Status :

Primary Care

ASPH

RSFT

SASH

SABP

Links :

Guidelines

SPC

37. Olsalazine sodium

Drug:

Olsalazine sodium

Indication :

Inflammatory bowel disease

Status :

Non Formulary

Formulations :

Capsules
Tablets

Restrictions / Comments:

Important

Licensed in mild ulcerative colitis

Formulary Status :

Primary Care

ASPH

RSFT

SASH

SABP

Links :

Guidelines

SPC